Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis

Brain

Volumn 135, Issue 6, 2012, Pages 1819-1833

  Elliott, Christina ^a   Lindner, Maren ^a   Arthur, Ariel ^a   Brennan, Kathryn ^b   Jarius, Sven ^c   Hussey, John ^a   Chan, Andrew ^d   Stroet, Anke ^d   Olsson, Tomas ^e   Willison, Hugh ^a,b   Barnett, Susan C ^a   Meinl, Edgar ^f,g   Linington, Christopher ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d ST JOSEF HOSPITAL   (Germany)

^e KAROLINSKA INSTITUTE   (Sweden)

^f MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^g UNIVERSITY OF MUNICH   (Germany)

Author keywords

autoantibody; axonal injury; demyelination; multiple sclerosis

Indexed keywords

AUTOANTIGEN; IMMUNOGLOBULIN G;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; AXONAL INJURY; CELL DIFFERENTIATION; CELL LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; FEMALE; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; MALE; MULTIPLE SCLEROSIS; MYELIN SHEATH; NEUROLOGIC DISEASE; OLIGODENDROGLIA; PLASMAPHERESIS; PRIORITY JOURNAL;

EID: 84861556651     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws105     Document Type: Article

References (80)

1. Appel SH, Bornstein MB. The application of tissue culture to the study of experimental allergic encephalomyelitis. II Serum factors responsible for demyelination. J Exp Med 1964; 119: 303-12.
2. Archelos JJ, Hartung HP. Pathogenetic role of autoantibodies in neurological diseases. Trends Neurosci 2000; 23: 317-27.
3. Barnett MH, Parratt JD, Cho ES, Prineas JW. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann Neurol 2009; 65: 32-46.
4. Bornstein MB, Murray MR. Serial observations on patterns of growth, myelin formation, maintenance and degeneration in cultures of newborn rat and kitten cerebellum. J Biophys Biochem Cytol 1958; 4: 499-504.
5. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009; 66: 630-43.
6. Breij EC, Heijnen P, van der Goes A, Teunissen CE, Polman CH, Dijkstra CD. Myelin flow cytometry assay detects enhanced levels of antibodies to human whole myelin in a subpopulation of multiple sclerosis patients. J Neuroimmunol 2006; 176: 106-14.
7. Brilot F, Dale RC, Selter RC, Grummel V, Kalluri SR, Aslam M, et al. Antibodies to Native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009; 66: 833-42.
8. Caspary EA. Humoral factors involved in immune processes in multiple sclerosis and allergic encephalomyelitis. Brit Med Bull 1977; 33: 50-3.
9. Charles P, Tait S, Faivre-Sarrailh C, Barbin G, Gunn-Moore F, Denisenko-Nehrbass N, et al. 2002) Neurofascin is a glial receptor for the para-nodin/Caspr-contactin axonal complex at the axoglial junction. Curr Biol 2002; 12: 217-20.
10. Derfuss T, Parikh K, Velhin S, Braun M, Mathey E, Krumbholz M, et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci USA 2009; 106: 8302-7.
11. Derfuss T, Linington C, Hohlfeld R, Meinl E. Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter. J Mol Med 2010; 88: 753-61.
12. Edwards JCW, Cambridge G. Prospects for B-cell-targeted therapy in autoimmune disease. Rheumatology 2005; 44: 151-6.
13. Gaertner S, de Graaf KL, Greve B, Weissert R. Antibodies against glyco-sylated native MOG are elevated in patients with multiple sclerosis. Neurology 2004; 63: 2381-3.
14. Genain CP, Cannella B, Hauser SL, Raine CS. Identification of autoanti-bodies associated with myelin damage in multiple sclerosis. Nat Med 1999; 5: 170-5.
15. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169-78.
16. Grundke-Iqbal I, Bornstein MB. Multiple sclerosis: serum gamma globulin and demyelination in organ culture. Neurology 1980; 30: 749-54.
17. Haase CG, Guggenmos J, Brehm U, Andersson M, Olsson T, Reindl M, et al. The fine specificity of the myelin oligodendrocyte glycoprotein autoantibody response in patients with multiple sclerosis and normal healthy controls. J Neuroimmunol 2001; 114: 220-5.
18. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with Rituximab in relapsing-remitting multiple sclerosis. New Eng J Med 2008; 358: 676-88.
19. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-71.
20. Huizinga R, Linington C, Amor S. Resistance is futile: anti-neuronal auto-immunity in multiple sclerosis. Trends Immunol 2008; 29: 54-60.
21. Iglesias A, Bauer J, Litzenburger T, Schubart A, Linington C. T-and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis. Glia 2001; 36: 220-34.
22. Ilyas AA, Chen ZW, Cook SD. Antibodies to sulfatide in cerebrospinal fluid of patients with multiple sclerosis. J Neuroimmunol 2003; 139: 76-80.
23. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010; 6: 383-92.
24. Kamm C, Zettl UK. Autoimmune disorders affecting both the central and peripheral nervous system. Autoimmun Rev 2012; 11: 196-202.
25. Kanter JL, Narayana S, Ho PP, Catz I, Warren KG, Sobel RA, et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat Med 2006; 12: 138-43.
26. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demye-lination: predictors of response. Neurology 2002; 58: 143-6.
27. Keegan M, Kö nig F, McClelland R, Brü ck W, Morales Y, Bitsch A, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005; 366: 579-82.
28. Lalive PH, Menge T, Delarasse C, Della Gaspera B, Pham-Dinh D, Villoslada P, et al. Antibodies to native myelin oligodendrocyte glyco-protein are serologic markers of early inflammation in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103: 2280-5.
29. Lalive PH, Häusler MG, Maurey H, Mikaeloff Y, Tardieu M, Wiendl H, et al. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler 2011; 17: 297-302.
30. Lampasona V, Franciotta D, Furlan R, Zanaboni S, Fazio R, Bonifacio E, et al. Similar low frequency of anti-MOG IgG and IgM in MS patients and healthy subjects. Neurology 2004; 62: 2092-4.
31. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythemato-sus. Arth Rheum 2002; 46: 2673-7.
32. Lebar R, Lubetzki C, Vincent C, Lombrail P, Boutry JM. The M2 auto-antigen of central nervous system myelin, a glycoprotein present in oligodendrocyte membrane. Clin Exp Immunol 1986; 66: 423-34.
33. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-12.
34. Lily O, Palace J, Vincent A. Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric study. Brain 2004; 127: 269-79.
35. Lindert RB, Haase CG, Brehm U, Linington C, Wekerle H, Hohlfeld R. Multiple sclerosis: B-and T-cell responses to the extracellular domain of the myelin oligodendrocyte glycoprotein. Brain 1999; 122: 2089-99.
36. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology 1976; 26: 1054-9.
37. Linington C, Lassmann H. Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyeli-nating activity with antibody titre to the myelin/oligodendrocyte glycoprotein (MOG). J Neuroimmunol 1987; 17: 61-9.
38. Linington C, Bradl M, Lassmann H, Brunner C, Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin oligodendro-cyte glycoprotein. Am J Pathol 1988; 130: 443-54.
39. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-17.
40. Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, et al. Complement activating antibodies to myelin oligodendrocyte glycopro-tein in neuromyelitis optica and related disorders. J Neuroinflam 2011; 8: 184.
41. Magana SM, Keegan BM, Weinshenker BG, Erickson BJ, Pittock SJ, Lennon VA, et al. Beneficial plasma exchange response in central nervous system inflammatory demyelination. Arch Neurol 2011; 68: 870-8.
42. Mathey EK, Derfuss T, Storch MK, Williams KR, Hales K, Woolley DR, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007; 204: 2363-72.
43. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
44. McLaughlin KA, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009; 183: 4067-76.
45. Meinl E, Derfuss T, Krumbholz M, Proebstel A-K, Hohlfeld R. Humoral autoimmunity in multiple sclerosis. J Neurol Sci 2011; 306: 180-2.
46. Niehaus A, Shi J, Grzenkowski M, Diers-Fenger M, Archelos J, Hartung HP, et al. Patients with active relapsing-remitting multiple sclerosis synthesize antibodies recognizing oligodendrocyte progenitor cell surface protein: implications for remyelination. Ann Neurol 2000; 48: 362-71.
47. Norton WT, Poduslo SE. Myelination in rat brain-method of myelin isolation. J Neurochem.1973. 21.749-57.
48. Pender MP. The pathogenesis of primary progressivie multiple sclerosis: antibody-mediated attack and no repair? J Clin Neurosci 2004; 11: 689-92.
49. Piddlesden SJ, Lassmann H, Zimprich F, Morgan BP, Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol 1993; 143: 555-64.
50. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
51. Prineas JW, Kwon EE, Cho ES, Sharer LR, Barnett MH, Oleszak EL, et al. Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001; 50: 646-57.
52. Probstel A-K, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, et al. Antibodies to MOG are transient in childhood acute disseminated en-cephalomyelitis. Neurology 2011; 77: 580-8.
53. Quintana FJ, Farez MF, Viglietta V, Iglesias AH, Merbl Y, Izquierdo G, et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci USA 2008; 105: 18889-94.
54. Raine CS, Cannella B, Hauser SL, Genain CP. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol 1999; 46: 144-60.
55. Ratcliffe CF, Westenbroek RE, Curtis R, Catterall WA. Sodium channel beta 1 and beta 3 subunits associate with neurofascin through their extracellular immunoglobulin-like domain. J Cell Biol 2001; 154: 427-34.
56. Reindl M, Linington C, Brehm U, Egg R, Dilitz E, Deisenhammer F, et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain 1999; 122: 2047-56.
57. Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003; 61: 1652-61.
58. Rinaldi S, Willison HJ. Ganglioside antibodies and neuropathies. Curr Opin Neurol 2008; 21: 540.
59. Rios JC, Rubin M, St Martin M, Downey RT, Einheber S, Rosenbluth J, et al. Paranodal interactions regulate expression of sodium channel subtypes and provide a diffusion barrier for the node of Ranvier. J Neurosci 2003; 23: 7001-11.
60. Schluesener HJ, Sobel RA, Linington C, Weiner HL. A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol 1987; 139: 4016-21.
61. Seil FJ, Falk GA, Kies MW, Alvord EC. The in vitro demyelinating activity of sera from guinea pigs sensitized with whole CNS and with purified encephalitogen. Exp Neurol 1968; 22: 545-55.
62. Seil FJ. Tissue-culture studies of demyelinating disease: a critical review. Ann Neurol 1977; 2: 345-55.
63. Seil FJ, Leiman AL, Kelly JM. Neuroelectric blocking factors in multiple sclerosis and normal human sera. Arch Neurol 1976; 33: 418-22.
64. Sorensen A, Moffat K, Thomson C, Barnett SC. Astrocytes, but not olfactory ensheathing cells or Schwann cells, promote myelination of CNS axons in vitro. Glia 2008; 56: 750-63.
65. Seil FJ, Smith ME, Leiman AL, Kelly JM. Myelination inhibiting and neu-roelectric blocking factors in experimental allergic encephalomyelitis. Science 1975; 187: 951-3.
66. Sospedra M, Martin R. Immunology of multiple sclerosis. Ann Rev Immunol 2005; 23: 683-747.
67. Steinman L. Multiple sclerosis: a two-stage disease. Nat Immunol 2001; 2: 762-4.
68. Storch MK, Stefferl A, Brehm U, Weissert R, Wallström E, Kerschensteiner M, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998; 8: 681-94.
69. Sun J, Link H, Olsson T, Xiao BG, Andersson G, Ekre HP, et al. T-cell and B-cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J Immunol 1991; 146: 1490-5.
70. Tait S, Gunn-Moore F, Collinson JM, Huang J, Lubetzki C, Pedraza L, et al. An oligodendrocyte cell adhesion molecule at the site of assembly of the paranodal axo-glial junction. J Cell Biol 2000; 150: 657-66.
71. Thomson CE, McCulloch M, Sorenson A, Barnett SC, Seed BV, Griffiths IR, et al. Myelinated, synapsing cultures of murine spinal cord: validation as an in vitro model of the central nervous system. Eur J Neurosci 2008; 28: 1518-35.
72. Traka M, Goutebroze L, Denisenko N, Bessa M, Nifli A, Havaki S, et al. Association of TAG-1 with Caspr2 is essential for the molecular organization of juxtaparanodal regions of myelinated fibers. J Cell Biol 2003; 162: 1161-72.
73. Trapp BD, Nishiyama A, Cheng D, Macklin W. Differentiation and death of premyelinating oligodendrocytes in developing rodent brain. J Cell Biol 1997; 137: 459-68.
74. Vamvakas EC, Pineda AA, Weinshenker BG. Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis. J Clin Apher 1995; 10: 163-70.
75. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psych 1985; 48: 1246-52.
76. Vyshkina T, Kalman B. Autoantibodies and neurodegeneration in multiple sclerosis. Lab Invest 2008; 88: 796-807.
77. Weber MS, Hemmer B, Cepok S. The role of antibodies in multiple sclerosis. Biochim Biophys Acta 2011; 1812: 239-245.
78. Weinshenker BG. Plasma exchange for severe attacks of inflammatory demyelinating diseases of the central nervous system. J Clin Apher 2001; 16: 39-42.
79. Xiao BG, Linington C, Link H. Antibodies to myelin oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J Neuroimmunol 1991; 31: 91-6.
80. Zhou D, Srivastava R, Nessler S, Grummel V, Sommer N, Brü ck W, et al. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA 2006; 103: 19057-62.